Thank you very much. Welcome to our Q2 2024 report. My name is Rene Aguilar, CEO of Calliditas. And I'm joined today by Richard Philipson, Chief Medical Officer. Fredrik Johansson, our Chief Financial Officer. And Maria Törnsén, President of North America.
Next page, please. I'd like to draw your attention to the disclaimer notice, which covers forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. And I refer to our public filings, including those containing risk factors. Next page please. So I'd like to review some of the key events in Q2, which included the conclusion of our Phase 3 study. And I figure with the readout of the open-label extension from which we reported nine-month efficacy and safety data similar to that observed in the active arm of the Phase 3 trial for those patients who were retreated with Nefecon after 15 months of observation.
In April, we reported our positive topline data from our Phase 2 proof of concept study. In head and neck cancer with a lead product candidate from our novel and unique NOx inhibitor platform. Such activity showed statistically significant impact on both progression-free survival as well as overall survival. And we also were granted a new patent by the US PTO for the treatment of certain cancers, with expiration in 2039. In May, our partner Everest Medicines launched in China, and the EMA issued a positive opinion for full approval of Kinpeygo in Europe.
We also participated in several important conferences where we presented additional data, which Richard will cover a bit later in the call. Next page, please. In the quarter, an offer was announced by Asahi Kasei, so on May 28th, our co-sign as a public cash offer for all shares in Calliditas for 208 Swedish crowns per share, valuing the company at approximately 1.2 billion Swedish crowns. The tender is presently ongoing, with the last day announced to be August 30th, subject to any potential extensions. The offer is recommended by the board, and around 45% of shareholders have entered into undertakings to accept the offer, subject to customary conditions.
Next page. So, with regards to commercial highlights of Q2. From a commercial perspective, this quarter was a record quarter in terms of revenues, with $46.3 million of net producer revenues, representing 90% growth over the same quarter last year. In addition, we saw record enrollments with 750 new enrollments and continued strong growth in new prescribers. The strong demand we're seeing is very encouraging, and we continue to see demand in the market for TARPEYO, with summer seasonality seemingly being less pronounced this year in comparison to last year, the team during this quarter undertook a very substantial number of PMT committee meetings, and the vast majority of major plans have now updated their rules to align with the new label.
We are expecting the full approval and this kind of reduced market access friction to continue to drive TARPEYO revenue growth for the year. Revenues from partners in the quarter amounted to 49 million Swedish crowns, representing growth of close to 300% compared to last quarter as Everest was launched in China also in May, operating profitability for the underlying business, excluding those costs related to the offer by Asahi Kasei for the quarter, came in at 70 million Swedish crowns, enabling us to reach our target of achieving operating profitability in the quarter. These excludes costs related to advisory services and provisions for incentive plans in connection with Asahi Kasei's offer, amounting to approximately 102 million Swedish crowns, taking us to an overall operating loss for the quarter of 31.5 million Swedish crowns. Achieving operating level profitability is a goal we were hoping to achieve and targeting in Q3, and we're obviously delighted that we reached this target already in Q2.
With regards to cash, we were almost cash neutral for the quarter. For the quarter, with cash burn amounting to approximately $700,000 or 7 million crowns. We believe there will be continued profitability at the operating level for the remainder of the year, excluding any deal-related costs, based on continued revenue growth from TARPEYO and the Everest franchise as a whole. Following the quarters in July, we reported our positive data from our Phase 2 trial in PBC (Primary Biliary Cholangitis), with both the 1200 milligram doses achieving statistical significance in terms of the primary endpoint. This was a heavily pretreated population, making this outcome even more rewarding. Richard will cover these details in more depth. Richard will cover this in more detail shortly. Also in July, Calliditas was granted full approval for the treatment of Primary Biliary Cholangitis in adults by the European Commission, which also triggered a €10 million milestone payment to be recognized in Q3. With that, I'd like to hand over to Richard, who will take us through the PBC data we discussed.